Canterbury DHB

Context

Prognosis

Smouldering Myeloma should not be treated. Overall, only 10% of SMM patients progress to symptomatic myeloma each year for the first 5 years. The risk decreases to 3% per year for the next 5 years and 1% per year thereafter. Risk of progression can be further estimated as follows:

 

Definition

Number who progress at 5 years

Median time to progression

Low

>30g/L and

<10% BM PC

15%

19 years

Medium

<30g/L but

>10% BM PC

43%

8years

High

>30g/L and

>10% BM PC

69%

2 years

About this Canterbury DHB document (5578):

Document Owner:

Sean Macpherson (see Who's Who)

Issue Date:

September 2014

Next Review:

September 2016

Keywords:

Note: Only the electronic version is controlled. Once printed, this is no longer a controlled document. Disclaimer

Topic Code: 5578